Document And Entity Information
Document And Entity Information - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2016 | Apr. 10, 2017 | |
Document Information [Line Items] | ||
Entity Registrant Name | CEN BIOTECH INC | |
Entity Central Index Key | 1,653,821 | |
Trading Symbol | cenb | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well-known Seasoned Issuer | No | |
Entity Common Stock, Shares Outstanding (in shares) | 10,525,000 | |
Entity Public Float | $ 0 | |
Document Type | 10-K | |
Document Period End Date | Dec. 31, 2016 | |
Document Fiscal Year Focus | 2,016 | |
Document Fiscal Period Focus | FY | |
Amendment Flag | false |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Current assets | ||
Cash and cash equivalents | $ 62,381 | $ 3,016 |
Total Current Assets | 62,381 | 3,016 |
PROPERTY, PLANT AND IMPROVEMENTS | ||
Property and equipment placed in service | 16,343 | |
Improvements in process | 1,270,115 | 8,292,111 |
OTHER ASSETS | ||
Advance on business acquisition | 425,328 | |
Intangible asset | 2,319,852 | |
Total Assets | 4,094,019 | 8,295,127 |
CURRENT LIABILITIES | ||
Accounts Payable | 157,055 | 164,503 |
Accounts Payable – related parties | 62,994 | 75,000 |
Accrued Interest | 2,717,478 | 1,228,023 |
Accrued Expenses | 840,584 | 593,719 |
Loans Payable – related parties | 846,448 | 1,313,680 |
Loans Payable | 9,962,287 | 9,865,615 |
Total Current Liabilities | 14,693,986 | 13,490,792 |
LONG-TERM DEBT | ||
Loans Payable – related party | 612,000 | |
Loans Payable – convertible notes | 1,391,602 | |
Total Liabilities | 17,473,710 | 14,102,792 |
STOCKHOLDERS’ DEFICIT | ||
Preferred Stock; unlimited authorized shares; 100,000 issued and outstanding | 10 | 10 |
Common Stock; unlimited authorized shares; 10,525,000 and 7,000,000 issued and outstanding as of December 31, 2016 and 2015, respectively | 85 | 82 |
Additional Paid in Capital | 10,000 | 0 |
Accumulated Deficit | (13,389,785) | (5,807,757) |
Total Stockholders’ Deficit | (13,389,690) | (5,807,665) |
Total liabilities and stockholders’ deficit | 4,094,019 | 8,295,127 |
Affiliated Entity [Member] | ||
CURRENT LIABILITIES | ||
Accrued Interest | 107,140 | 250,252 |
President [Member] | ||
LONG-TERM DEBT | ||
Loans Payable – convertible notes | $ 1,388,122 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - shares | Dec. 31, 2016 | Dec. 31, 2015 |
Preferred stock, shares issued (in shares) | 100,000 | 100,000 |
Preferred stock, shares outstanding (in shares) | 100,000 | 100,000 |
Common stock, shares issued (in shares) | 10,525,000 | 7,000,000 |
Common stock, shares outstanding (in shares) | 10,525,000 | 7,000,000 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Revenue | ||
Sale of equipment | $ 2,321 | |
Operating expenses | ||
Salary and Consulting Fees | 195,739 | 223,411 |
Stock Based Compensation | 10,000 | |
General and Administrative | 870,303 | 942,258 |
Tangible Asset Impairment Charges | 4,835,596 | |
Foreign Exchange Loss (Gain) | 47,539 | (121,146) |
Total Expense | 5,980,856 | 1,044,523 |
Loss from operations | (5,980,856) | (1,044,523) |
Other Expenses | ||
Interest | 1,313,319 | 1,178,708 |
Interest – related parties | 287,853 | 183,324 |
Total other expenses | 1,601,172 | 1,362,032 |
Net Loss | $ (7,582,028) | $ (2,406,555) |
Net Loss Per Share: Basic And Diluted (in dollars per share) | $ (0.92) | $ (0.34) |
Weighted Average Number of Shares Outstanding: Basic And Diluted (in shares) | 8,222,827 | 7,000,000 |
Affiliated Entity [Member] | ||
Operating expenses | ||
Salary and Consulting Fees | $ 24,000 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net Loss | $ (7,582,028) | $ (2,406,555) |
Adjustments to reconcile net gain (loss) to net cash used in operating activities | ||
Depreciation & Amortization | 45,605 | |
Impairment Loss | 4,835,596 | |
Stock-Based Compensation | 10,000 | |
Foreign Exchange Loss | (47,539) | |
Changes in | ||
Due from Creative Edge Nutrition Inc. | 167,456 | |
Accounts Payable | 102,978 | 613,248 |
Accrued Interest and Other Expenses | 1,953,242 | 1,362,032 |
Cash Flows Used in Operating Activities | (682,146) | (263,819) |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
Loans to CEN Ukraine | (425,328) | |
Leasehold Improvements In Progress | 7,265 | (47,672) |
Purchase of Light Patent (paid in cash) | (7,837) | |
Total Cash Flows Used in Investing Activities | (425,900) | (47,672) |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Proceeds From Convertible Loans | 1,167,412 | 270,074 |
Total Cash Flows Provided by Financing Activities | 1,167,412 | 270,074 |
Net increase (decrease) | 59,366 | (41,417) |
Cash, Beginning of Period | 3,016 | 44,433 |
Cash, End of Period | 62,381 | 3,016 |
NON-CASH TRANSACTIONS | ||
Loans Payable reclassified to Convertible Notes | 206,541 | |
Loans Payable- RP reclassified to Convertible Notes- RP | 538,943 | |
Accrued Expense reclassified to Notes Payable | 105,206 | |
Accrued Interest reclassified to Notes Payable | 254,829 | |
Construction in Progress exchanged for Patent | 1,096,816 | |
Land exchanged for Patent | 1,064,651 | |
Loans Payable exchanged for Patent | 202,663 | |
Stock Issued in exchange for Patent | 3 | |
Patent Acquired with above consideration | $ 2,364,133 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholder's Deficit - USD ($) | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2014 | 100,000 | 7,000,000 | |||
Balance at Dec. 31, 2014 | $ 10 | $ 82 | $ (3,401,202) | $ (3,401,110) | |
Net loss | (2,406,555) | (2,406,555) | |||
Balance (in shares) at Dec. 31, 2015 | 100,000 | 7,000,000 | |||
Balance at Dec. 31, 2015 | $ 10 | $ 82 | (5,807,757) | (5,807,665) | |
Net loss | (7,582,028) | (7,582,028) | |||
Balance (in shares) at Dec. 31, 2016 | 100,000 | 10,525,000 | |||
Balance at Dec. 31, 2016 | $ 10 | $ 85 | $ 10,000 | (13,399,785) | (13,389,690) |
Shares issued in connection with Patent acquisition (in shares) | 3,125,000 | ||||
Shares issued in connection with Patent acquisition | $ 3 | 3 | |||
Shares issued for services (in shares) | 400,000 | ||||
Shares issued for services | $ 10,000 | $ (10,000) |
Note 1 - Organization and Conso
Note 1 - Organization and Consolidation | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | NOTE 1 CEN Biotech, Inc. (“CEN” or the “Company”) was incorporated in Canada on August 4, 2013 February 29, 2016 CEN is an early stage Canadian biopharmaceutical company founded to integrate agronomical and pharmaceutical principles for the purposes of growing, selling, processing and delivering pharmaceutical-grade medical marijuana in its pure and extracted form to patients in accordance with Health Canada’s newly-formed Marihuana for Medical Purposes Regulations (MMPR). CEN is actively pursuing business opportunities globally with the intent to grow, sell, process and deliver pharmaceutical grade medical marijuana in various drug delivery mechanisms within nations where it is legal. The company’s financial statement are consolidated and include the accounts of CEN Biotech Inc. and CEN Holdings Inc. CEN Holdings Inc. was incorporated in Michigan as a non-operating wholly owned subsidiary of CEN Biotech Inc. Its purpose is to ease and facilitate US banking transactions. Intercompany transactions are eliminated in consolidation. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | NOTE 2 Basis of Accounting The Company’s financial statements are prepared using the accrual method of accounting in accordance with generally accepted accounting principles in the United States. The Company has elected a calendar year end. Use of Estimates and Assumptions Preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. The Company has adopted the provisions of ASC 260. Cash and Cash Equivalents For purposes of the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with maturity of three Fair Value of Financial Instruments The fair value of our financial instruments reflects the amounts that we estimate to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company’s financial instruments including cash and accounts payable are assumed to be carried at fair value due to their short term maturities. Property and Equipment Property and equipment is recorded at cost. Depreciation and amortization of property and equipment is provided using the straight-line method for financial reporting purposes at deemed sufficient to recover the cost over the estimated useful lives of the assets. We have recorded 1,325 December 31, 2016. Classification Estimated Useful Life (in years) Furniture and fixtures 7 Equipment 5 Computer equipment 3 The cost of asset additions and improvements that extend the useful lives of property and equipment are capitalized. Routine maintenance and repair items are charged to current operations. The original cost and accumulated depreciation of asset dispositions are removed from the accounts and any gain or loss is reflected in the statement of operations in the period of disposition. CEN Biotech capitalizes expenditures for real property improvements including improvements to leased property and reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment is performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset's fair value and its carrying value. If quoted market prices are not available, Cen Biotech estimates fair value using a discounted value of estimated future cash flows. Impairment of Long-Lived Assets The Company's recently acquired a patent which is accounted for as a definite-lived intangible asset in accordance with ASC 360 360"). We periodically review the carrying value of our long-lived assets, such as property and equipment, and intangibles, including goodwill, whenever current events or circumstances indicate that the carrying amount of an asset may third third Revenue Recognition The Company applies paragraph 605 10 S99 1 Research and Development Expenditures Cen Biotech expenses all research and development expenses when incurred. Income Taxes Income taxes will be provided in accordance with ASC 740, Income Taxes Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Foreign Currency Transactions and Balances Foreign currency transactions in Canadian dollars are recorded in the Company’s financial records in US Dollars at the exchange rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are subsequently remeasured at the balance sheet date exchange rate into the functional currency. All gains and losses resulting from the settlement of foreign currency transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies are included in the income statement. Loss per Share Net loss per common share is computed pursuant to ASC 260 10 45. first no December 31, 2016 2015. Subsequent Events The Company follows the guidance in ASC 855 10 50 2010 09 Recently Issued Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect as of the date of the issuance of these financial statements. The following pronouncements will significantly impact future reporting of financial positon and results of operations. Management is currently assessing implementation. FASB Accounting Standards Update No. 2017 01, Business Combinations (Topic 805): The FASB has issued Accounting Standards Update (ASU) No. 2017 01, 805): For public companies, the amendments are effective for annual periods beginning after December 15, 2017, FASB Accounting Standards Update No. 2016 02 Leases (Topic 842) The FASB has issued its new lease accounting guidance in Accounting Standards Update (ASU) No. 2016 02, 842). Under the new guidance, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: ● A lease liability, which is a lessee‘s obligation to make lease payments arising from a lease, measured on a discounted basis; and ● A right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ● Under the new guidance, lessor accounting is largely unchanged. Certain targeted improvements were made to align, where necessary, lessor accounting with the lessee accounting model and Topic 606, ● The new lease guidance simplified the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Lessees will no longer be provided with a source of off-balance sheet financing. Public business entities should apply the amendments in ASU 2016 02 December 15, 2018, January 1, 2019, FASB Accounting Standards Update No. 2016 09, 718): The FASB has issued Accounting Standards Update (ASU) No. 2016 09, Compensation - Stock Compensation (Topic 718): The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. For public companies, the amendments are effective for annual periods beginning after December 15, 2016, December 15, 2017, December 15, 2018. FASB Accounting Standards Update No. 2016 10, 606): The FASB has issued Accounting Standards Update No. 2016 10, 606): two 606: 606. The effective date and transition requirements for the amendments are the same as the effective date and transition requirements in Topic 606. December 15, 2017, January 1, 2018, December 15, 2016, one |
Note 3 - Going Concern
Note 3 - Going Concern | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | NOTE 3 The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As reflected in the accompanying financial statements, the Company had an accumulated deficit of $13,389,785 December 31, 2016, While the Company is attempting to obtain a license from Health Canada and generate revenues, the Company’s cash position may The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. |
Note 4 - Property, Plant and Im
Note 4 - Property, Plant and Improvements | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | NOTE 4 Property and equipment placed in service as of December 31, 2016 2015, Description 2016 2015 Furniture and equipment $ 17,668 $ - Accumulated depreciation 1,325 - Net furniture and equipment $ 16,343 $ - We have recorded $1,325 December 31, 2016 2015, Property and improvements not placed in service as of December 31, 2016 2015, Description 2016 2015 Leasehold improvements $ 6,105,711 $ 6,130,644 Accumulated impairment 4,835,596 - Net Leasehold Improvements 1,270,115 - Land - 1,064,651 Construction in progress - 1,096,816 Net leasehold improvements $ 1,270,115 $ 8,292,111 The Company’s fixed assets consist of the following: a property at 135 20 $1,064,651 135 2014. September 2016, 135 12 The Company leases 20 8). 2014, 8 The assets will be classified on the balance sheet as improvements in progress until the Company obtains a license to produce pharmaceutical-grade medical marijuana and is able to begin operations. Until that time, the Company cannot make the final additions that will be necessary for the sites to function as growing spaces. Although there are currently grow rooms outfitted and ready to grow. The amount listed represents the capitalized costs the Company incurred in constructing the improvements, some of which were paid to related parties (see Note 7). Our impairment assessment as of December 31, 2016 20 $4,835,596 20 |
Note 5 - Advance on Business Ac
Note 5 - Advance on Business Acquisition | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Advance on Business Acquisition [Text Block] | NOTE 5 During the year ended December 31, 2016, $425,328 We have performed an impairment assessment of this advance on the acquisition of an operating business and have concluded that there was no need to impair the value of this asset as of December 31, 2016. |
Note 6 - Intangible Asset
Note 6 - Intangible Asset | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Intangible Assets Disclosure [Text Block] | NOTE 6 – INTANGIBLE ASSET Intangible asset as of December 31, 2016 2015, Description 2016 2015 Lighting patent $ 2,364,133 $ - Amortization 44,281 - Net light patent $ 2,319,852 $ - On September 12, 2016, The material consideration given by Company includes: ● 3,125,000 180 ● The transfer of real properties located at 135 $2,161,467 1517 1525 $182,488. Description 2016 2015 Lighting patent $ 2,364,133 $ - Amortization 44,281 - Net light patent $ 2,319,852 $ - ● Non-material consideration includes employment by the principal of the acquiree with an operating company to be formed to realize the potential of the acquired technology. The Company plans to explore manufacturing operations and licensing opportunities across multiple industries such as horticultural, automotive, industrial and commercial lighting. The assets acquired other than the patent included old machinery and raw materials. The company has assigned no value to these since their value was not relevant to or calculated in the company’s offer for acquisition. Therefore, no impairment will be necessary if these assets are disposed of. We have performed an impairment assessment on this patent and have concluded that there was no need to impair the value of this asset as of December 31, 2016. |
Note 7 - Short Term Loans Payab
Note 7 - Short Term Loans Payable | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Short-term Debt [Text Block] | NOTE 7 – SHORT TERM LOANS PAYABLE Short-term loans payable consist of the following at December 31, 2016 2015: Description 2016 2015 Short-term loan payable to Global Holdings International, LLC, which bears interest at 12% per annum. This note originally matured on June 30, 2015 and became due on demand. Subsequently, the maturity date was extended to June 30, 2016, secured by the Company’s equipment. $ 9,675,000 $ 9,865,615 Short-term mortgage payable to ARG & Pals, Inc., for the original amount of $385,000 CAD. It bears interest at 22% per annum with a maturity of March 21, 2017. 287,287 - Total Short-term Loan Payable $ 9,962,287 $ 9,865,615 |
Note 8 - Short Term Loans Payab
Note 8 - Short Term Loans Payable - Related Party | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Short-term Debt, Related Party [Text Block] | NOTE 8 – SHORT TERM LOANS PAYABLE - RELATED PARTY Short-term loans payable related party consist of the following at December 31, 2016 2015: Description 2016 2015 Short-term related party loan payable to Bill Chaaban, President of Cen Biotech, which bears an interest at 10% per annum. This is an unsecured loan with a maturity date of December 31, 2017. $ 244,948 $ 718,679 Short-term related party loan payable to Jeff Thomas, former director of Creative Edge, which bears an interest at 10% annum. This is an unsecured loan with a maturity date of December 31, 2017. 601,500 595,000 Total Short-term Loan Payable Relate Party $ 846,448 $ 1,313,679 |
Note 9 - Long Term Convertible
Note 9 - Long Term Convertible Notes | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Long-term Debt [Text Block] | NOTE 9 – LONG TERM CONVERTIBLE NOTES Long-term convertible notes consist of the following at December 31, 2016 2015: Description 2016 2015 Long-term convertible notes payable to multiple private investors bearing an interest at 5% annum with conversion rights totaling up to 873,225 common shares. All notes have a maturity date of 2 years from its inception. $ 1,167,412 $ - Long-term convertible notes payable to Joe Byrne which bears interest at 12% annum with a maturity due date of Augusts 18, 2018. 224,190 - Total Long-Term Convertible Notes $ 1,391,602 $ - |
Note 10 - Long Term Convertible
Note 10 - Long Term Convertible Notes Related Party | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Long-term Convertible Notes Related Party [Text Block] | NOTE 10 – LONG TERM CONVERTIBLE NOTES RELATED PARTY Long-term convertible notes related party consist of the following at December 31, 2016 2015: Description 2016 2015 Long-term convertible note related party due to Bill Chaaban, President of Cen Biotech, which bears an interest at 12% per annum. This note is convertible to 871,576 common shares with a maturity due date of August 17, 2018. $ 1,388,121 $ - Total Long-Term Convertible Notes Related Party $ 1,388,121 $ - |
Note 11 - Income Taxes
Note 11 - Income Taxes | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | NOTE 11 – INCOME TAXES As of December 31, 2016, $3,120,000 may may No December 31, 2016 2015. |
Note 12 - Stockholder's Deficit
Note 12 - Stockholder's Deficit | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 12 – STOCKHOLDER’S DEFICIT The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. On August 4, 2013, 75 $75 December 18, 2013, 6,999,925 $7 7,000,000 February 29, 2016 In addition, in December 2014 100,000 500 $100 |
Note 13 - Related Party Transac
Note 13 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | NOTE 13 – RELATED PARTY TRANSACTIONS The planning and construction of CEN’s facility was overseen by R.X.N.B., Inc. which is 45% December 31, 2014, $2,439,900 $1,542,000 $897,900 The Company has received loans from several related parties, as described above in Note 5. The Company leases the site at 20 9 Occasionally, Creative and CEN paid individually for costs incurred by both companies or by the other company. During 2015 $167,456 There are loans of $425,328 51% |
Note 14 - Contingencies and Unc
Note 14 - Contingencies and Uncertainties | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 1 4 – COMMITMENTS AND CONTINGENCIES On March 11, 2015, April 10, 2015 The Company’s President signed a five August 2013 $1,200,000 February. The Company entered into a sublease with Creative on September 1, 2013 10.4 4). March 31, 2018 $339,000, two one 27,000 one 53,000 4,000 December 31, 2016 2015, $552,934 $289,159, Fiscal Year Ending December 31, Amount (CAD) 2016 $ 339,000 2017 339,000 2018 84,750 Total $ 762,750 |
Note 15 - Stock-based Compensat
Note 15 - Stock-based Compensation | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | NOTE 1 5 – STOCK BASED COMPENSATION The Company uses the Enterprise Value methodology for stock-based compensation and therefore all awards to employees and non-employees estimated based on the Enterprise Value on the date of the grant and expense on the issuance date. |
Note 16 - Business Segments
Note 16 - Business Segments | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | NOTE 1 6 – BUSINESS SEGMENTS The Company is currently planning to operate within three |
Note 17 - Subsequent Events
Note 17 - Subsequent Events | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | NOTE 1 7 - SUBSEQUENT EVENTS In January 2017, 20 $4,000.00 3 Between January March 2017 $1,066,475 666,547 In March 2017 In March 2017 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2016 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Accounting The Company’s financial statements are prepared using the accrual method of accounting in accordance with generally accepted accounting principles in the United States. The Company has elected a calendar year end. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates and Assumptions Preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. The Company has adopted the provisions of ASC 260. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents For purposes of the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with maturity of three |
Fair Value Measurement, Policy [Policy Text Block] | Fair Value of Financial Instruments The fair value of our financial instruments reflects the amounts that we estimate to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company’s financial instruments including cash and accounts payable are assumed to be carried at fair value due to their short term maturities. |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment is recorded at cost. Depreciation and amortization of property and equipment is provided using the straight-line method for financial reporting purposes at deemed sufficient to recover the cost over the estimated useful lives of the assets. We have recorded 1,325 December 31, 2016. Classification Estimated Useful Life (in years) Furniture and fixtures 7 Equipment 5 Computer equipment 3 The cost of asset additions and improvements that extend the useful lives of property and equipment are capitalized. Routine maintenance and repair items are charged to current operations. The original cost and accumulated depreciation of asset dispositions are removed from the accounts and any gain or loss is reflected in the statement of operations in the period of disposition. CEN Biotech capitalizes expenditures for real property improvements including improvements to leased property and reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment is performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset's fair value and its carrying value. If quoted market prices are not available, Cen Biotech estimates fair value using a discounted value of estimated future cash flows. |
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] | Impairment of Long-Lived Assets The Company's recently acquired a patent which is accounted for as a definite-lived intangible asset in accordance with ASC 360 360"). We periodically review the carrying value of our long-lived assets, such as property and equipment, and intangibles, including goodwill, whenever current events or circumstances indicate that the carrying amount of an asset may third third |
Revenue Recognition, Policy [Policy Text Block] | Revenue Recognition The Company applies paragraph 605 10 S99 1 |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Expenditures Cen Biotech expenses all research and development expenses when incurred. |
Income Tax, Policy [Policy Text Block] | Income Taxes Income taxes will be provided in accordance with ASC 740, Income Taxes Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign Currency Transactions and Balances Foreign currency transactions in Canadian dollars are recorded in the Company’s financial records in US Dollars at the exchange rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are subsequently remeasured at the balance sheet date exchange rate into the functional currency. All gains and losses resulting from the settlement of foreign currency transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies are included in the income statement. |
Earnings Per Share, Policy [Policy Text Block] | Loss per Share Net loss per common share is computed pursuant to ASC 260 10 45. first no December 31, 2016 2015. |
Subsequent Events, Policy [Policy Text Block] | Subsequent Events The Company follows the guidance in ASC 855 10 50 2010 09 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Issued Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect as of the date of the issuance of these financial statements. The following pronouncements will significantly impact future reporting of financial positon and results of operations. Management is currently assessing implementation. FASB Accounting Standards Update No. 2017 01, Business Combinations (Topic 805): The FASB has issued Accounting Standards Update (ASU) No. 2017 01, 805): For public companies, the amendments are effective for annual periods beginning after December 15, 2017, FASB Accounting Standards Update No. 2016 02 Leases (Topic 842) The FASB has issued its new lease accounting guidance in Accounting Standards Update (ASU) No. 2016 02, 842). Under the new guidance, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: ● A lease liability, which is a lessee‘s obligation to make lease payments arising from a lease, measured on a discounted basis; and ● A right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ● Under the new guidance, lessor accounting is largely unchanged. Certain targeted improvements were made to align, where necessary, lessor accounting with the lessee accounting model and Topic 606, ● The new lease guidance simplified the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Lessees will no longer be provided with a source of off-balance sheet financing. Public business entities should apply the amendments in ASU 2016 02 December 15, 2018, January 1, 2019, FASB Accounting Standards Update No. 2016 09, 718): The FASB has issued Accounting Standards Update (ASU) No. 2016 09, Compensation - Stock Compensation (Topic 718): The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. For public companies, the amendments are effective for annual periods beginning after December 15, 2016, December 15, 2017, December 15, 2018. FASB Accounting Standards Update No. 2016 10, 606): The FASB has issued Accounting Standards Update No. 2016 10, 606): two 606: 606. The effective date and transition requirements for the amendments are the same as the effective date and transition requirements in Topic 606. December 15, 2017, January 1, 2018, December 15, 2016, one |
Note 4 - Property, Plant and 25
Note 4 - Property, Plant and Improvements (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Property and Improvements Not Placed in Service [Member] | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | Description 2016 2015 Leasehold improvements $ 6,105,711 $ 6,130,644 Accumulated impairment 4,835,596 - Net Leasehold Improvements 1,270,115 - Land - 1,064,651 Construction in progress - 1,096,816 Net leasehold improvements $ 1,270,115 $ 8,292,111 |
Property and Equipment Placed in Service [Member] | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | Description 2016 2015 Furniture and equipment $ 17,668 $ - Accumulated depreciation 1,325 - Net furniture and equipment $ 16,343 $ - |
Note 6 - Intangible Asset (Tabl
Note 6 - Intangible Asset (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | Description 2016 2015 Lighting patent $ 2,364,133 $ - Amortization 44,281 - Net light patent $ 2,319,852 $ - |
Note 7 - Short Term Loans Pay27
Note 7 - Short Term Loans Payable (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Short-term Debt [Table Text Block] | Description 2016 2015 Short-term loan payable to Global Holdings International, LLC, which bears interest at 12% per annum. This note originally matured on June 30, 2015 and became due on demand. Subsequently, the maturity date was extended to June 30, 2016, secured by the Company’s equipment. $ 9,675,000 $ 9,865,615 Short-term mortgage payable to ARG & Pals, Inc., for the original amount of $385,000 CAD. It bears interest at 22% per annum with a maturity of March 21, 2017. 287,287 - Total Short-term Loan Payable $ 9,962,287 $ 9,865,615 |
Note 8 - Short Term Loans Pay28
Note 8 - Short Term Loans Payable - Related Party (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Short-term Debt [Table Text Block] | Description 2016 2015 Short-term loan payable to Global Holdings International, LLC, which bears interest at 12% per annum. This note originally matured on June 30, 2015 and became due on demand. Subsequently, the maturity date was extended to June 30, 2016, secured by the Company’s equipment. $ 9,675,000 $ 9,865,615 Short-term mortgage payable to ARG & Pals, Inc., for the original amount of $385,000 CAD. It bears interest at 22% per annum with a maturity of March 21, 2017. 287,287 - Total Short-term Loan Payable $ 9,962,287 $ 9,865,615 |
Short-term Related Party Loan Payable [Member] | |
Notes Tables | |
Schedule of Short-term Debt [Table Text Block] | Description 2016 2015 Short-term related party loan payable to Bill Chaaban, President of Cen Biotech, which bears an interest at 10% per annum. This is an unsecured loan with a maturity date of December 31, 2017. $ 244,948 $ 718,679 Short-term related party loan payable to Jeff Thomas, former director of Creative Edge, which bears an interest at 10% annum. This is an unsecured loan with a maturity date of December 31, 2017. 601,500 595,000 Total Short-term Loan Payable Relate Party $ 846,448 $ 1,313,679 |
Note 9 - Long Term Convertibl29
Note 9 - Long Term Convertible Notes (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Long-term Debt Instruments [Table Text Block] | Description 2016 2015 Long-term convertible notes payable to multiple private investors bearing an interest at 5% annum with conversion rights totaling up to 873,225 common shares. All notes have a maturity date of 2 years from its inception. $ 1,167,412 $ - Long-term convertible notes payable to Joe Byrne which bears interest at 12% annum with a maturity due date of Augusts 18, 2018. 224,190 - Total Long-Term Convertible Notes $ 1,391,602 $ - |
Note 10 - Long Term Convertib30
Note 10 - Long Term Convertible Notes Related Party (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Long-term Debt Instruments [Table Text Block] | Description 2016 2015 Long-term convertible notes payable to multiple private investors bearing an interest at 5% annum with conversion rights totaling up to 873,225 common shares. All notes have a maturity date of 2 years from its inception. $ 1,167,412 $ - Long-term convertible notes payable to Joe Byrne which bears interest at 12% annum with a maturity due date of Augusts 18, 2018. 224,190 - Total Long-Term Convertible Notes $ 1,391,602 $ - |
Long-term Convertible Note Related Party [Member] | |
Notes Tables | |
Schedule of Long-term Debt Instruments [Table Text Block] | Description 2016 2015 Long-term convertible note related party due to Bill Chaaban, President of Cen Biotech, which bears an interest at 12% per annum. This note is convertible to 871,576 common shares with a maturity due date of August 17, 2018. $ 1,388,121 $ - Total Long-Term Convertible Notes Related Party $ 1,388,121 $ - |
Note 14 - Contingencies and U31
Note 14 - Contingencies and Uncertainties (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | Fiscal Year Ending December 31, Amount (CAD) 2016 $ 339,000 2017 339,000 2018 84,750 Total $ 762,750 |
Note 2 - Summary of Significa32
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) shares in Thousands | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Depreciation | $ 1,325 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 0 | 0 |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment, Useful Life | 7 years | |
Equipment [Member] | ||
Property, Plant and Equipment, Useful Life | 5 years | |
Computer Equipment [Member] | ||
Property, Plant and Equipment, Useful Life | 3 years |
Note 3 - Going Concern (Details
Note 3 - Going Concern (Details Textual) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Retained Earnings (Accumulated Deficit) | $ (13,389,785) | $ (5,807,757) |
Note 4 - Property, Plant and 34
Note 4 - Property, Plant and Improvements (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Depreciation | $ 1,325 | ||
Tangible Asset Impairment Charges | 4,835,596 | ||
Property at 135 North Rear Road [Member] | |||
Payments to Acquire Land Held-for-use | $ 1,064,651 | ||
Leasehold Improvements At 20 North Rear Road [Member] | |||
Tangible Asset Impairment Charges | $ 4,835,596 |
Note 4 - Property, Plant and 35
Note 4 - Property, Plant and Improvements - Property and Equipment Placed in Service (Details) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Net furniture and equipment | $ 16,343 | |
Property and Equipment Placed in Service [Member] | ||
Furniture and equipment | 17,668 | |
Accumulated depreciation | 1,325 | |
Net furniture and equipment | $ 16,343 |
Note 4 - Property, Plant and 36
Note 4 - Property, Plant and Improvements - Property and Improvements Not Placed in Service (Details) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Net leasehold improvements | $ 1,270,115 | $ 8,292,111 |
Property and Improvements Not Placed in Service [Member] | ||
Leasehold improvements | 6,105,711 | 6,130,644 |
Accumulated impairment | 4,835,596 | |
Net Leasehold Improvements | 1,270,115 | |
Land | 1,064,651 | |
Construction in progress | 1,096,816 | |
Net leasehold improvements | $ 1,270,115 | $ 8,292,111 |
Note 5 - Advance on Business 37
Note 5 - Advance on Business Acquisition (Details Textual) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Advance on Business Acquisition | $ 425,328 |
Note 6 - Intangible Asset (Deta
Note 6 - Intangible Asset (Details Textual) - Acquisition of Assets from Tesla Digital, Inc. and Stevan Pokrajac[Member] | Sep. 12, 2016USD ($)shares |
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares | 3,125,000 |
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Maximum Period from Closing Date to Issue Shares | 180 days |
Noncash or Part Noncash Acquisition, Noncash Consideration, Carrying Value of Properties to be Transferred | $ 2,161,467 |
Noncash or Part Noncash Acquisition, Noncash Consideration, Original Cost of Property Transferred | $ 182,488 |
Note 6 - Intangible Asset - Int
Note 6 - Intangible Asset - Intangible Asset (Details) - Lighting Patent [Member] - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Lighting patent | $ 2,364,133 | |
Amortization | 44,281 | |
Net light patent | $ 2,319,852 |
Note 7 - Short Term Loans Pay40
Note 7 - Short Term Loans Payable - Short Term Loans Payable (Details) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Short-term Loan Payable | $ 9,962,287 | $ 9,865,615 |
Short-term Loan Payable to Global Holdings International, LLC [Member] | ||
Short-term Loan Payable | 9,675,000 | 9,865,615 |
Short-term Mortgage Payable to ARG & Pals, Inc. [Member] | ||
Short-term Loan Payable | $ 287,287 |
Note 7 - Short Term Loans Pay41
Note 7 - Short Term Loans Payable - Short Term Loans Payable (Details) (Parentheticals) - CAD | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Short-term Loan Payable to Global Holdings International, LLC [Member] | ||
Interest Rate | 12.00% | 12.00% |
Maturity Date | Jun. 30, 2016 | Jun. 30, 2016 |
Short-term Mortgage Payable to ARG & Pals, Inc. [Member] | ||
Interest Rate | 22.00% | 22.00% |
Maturity Date | Mar. 21, 2017 | Mar. 21, 2017 |
Original Amount | CAD 385,000 | CAD 385,000 |
Note 8 - Short Term Loans Pay42
Note 8 - Short Term Loans Payable - Related Party - Short Term Loans Payable Related Party (Details) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Short-term Loan Payable | $ 9,962,287 | $ 9,865,615 |
Short-term Related Party Loan Payable [Member] | ||
Short-term Loan Payable | 846,448 | 1,313,679 |
Short-term Related Party Loan Payable [Member] | Bill Chaaban, President of Cen Biotech [Member] | ||
Short-term Loan Payable | 244,948 | 718,679 |
Short-term Related Party Loan Payable [Member] | Jeff Thomas, Former Director of Creative Edge [Member] | ||
Short-term Loan Payable | $ 601,500 | $ 595,000 |
Note 8 - Short Term Loans Pay43
Note 8 - Short Term Loans Payable - Related Party - Short Term Loans Payable Related Party (Details) (Parentheticals) - Short-term Related Party Loan Payable [Member] | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Bill Chaaban, President of Cen Biotech [Member] | ||
Interest Rate | 10.00% | 10.00% |
Maturity Date | Dec. 31, 2017 | Dec. 31, 2017 |
Jeff Thomas, Former Director of Creative Edge [Member] | ||
Interest Rate | 10.00% | 10.00% |
Maturity Date | Dec. 31, 2017 | Dec. 31, 2017 |
Note 9 - Long Term Convertibl44
Note 9 - Long Term Convertible Notes - Long Term Convertible Notes (Details) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Long-term Convertible Notes Payable to Multiple Private Investors [Member] | ||
Long-Term Convertible Notes | $ 1,167,412 | |
Long-term Convertible Notes Payable to Joe Byrne [Member] | ||
Long-Term Convertible Notes | 224,190 | |
Long-term Convertible Notes [Member] | ||
Long-Term Convertible Notes | $ 1,391,602 |
Note 9 - Long Term Convertibl45
Note 9 - Long Term Convertible Notes - Long Term Convertible Notes (Details) (Parentheticals) | 12 Months Ended |
Dec. 31, 2016 | |
Long-term Convertible Notes Payable to Multiple Private Investors [Member] | |
Interest Rate | 5.00% |
Debt Instrument, Convertible, Number of Equity Instruments | 873,225 |
Term (Year) | 2 years |
Long-term Convertible Notes Payable to Joe Byrne [Member] | |
Interest Rate | 12.00% |
Note 10 - Long Term Convertib46
Note 10 - Long Term Convertible Notes Related Party - Long Term Convertible Notes Related Party (Details) - Long-term Convertible Note Related Party [Member] - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Long-Term Convertible Notes Related Party | $ 1,388,121 | |
Bill Chaaban, President of Cen Biotech [Member] | ||
Long-Term Convertible Notes Related Party | $ 1,388,121 |
Note 10 - Long Term Convertib47
Note 10 - Long Term Convertible Notes Related Party - Long Term Convertible Notes Related Party (Details) (Parentheticals) - Bill Chaaban, President of Cen Biotech [Member] - Long-term Convertible Note Related Party [Member] | 12 Months Ended |
Dec. 31, 2016 | |
Interest Rate | 12.00% |
Debt Instrument, Convertible, Number of Equity Instruments | 871,576 |
Maturity Date | Aug. 17, 2018 |
Note 11 - Income Taxes (Details
Note 11 - Income Taxes (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Operating Loss Carryforwards | $ 3,120,000 | |
Income Tax Expense (Benefit) | $ 0 | $ 0 |
Note 12 - Stockholder's Defic49
Note 12 - Stockholder's Deficit (Details Textual) | Dec. 18, 2013USD ($)shares | Aug. 04, 2013USD ($)shares | Dec. 31, 2014USD ($)shares | Dec. 31, 2016shares | Dec. 31, 2015shares |
Stock Issued During Period, Shares, New Issues | 6,999,925 | 75 | |||
Proceeds from Issuance of Common Stock | $ | $ 7 | $ 75 | |||
Common Stock, Shares, Outstanding | 7,000,000 | 10,525,000 | 7,000,000 | ||
Preferred Stock [Member] | President [Member] | |||||
Stock Issued During Period, Shares, New Issues | 100,000 | ||||
Preferred Stock, Voting Rights Per Each Share | 500 | ||||
Stock Issued During Period, Value, New Issues | $ | $ 100 |
Note 13 - Related Party Trans50
Note 13 - Related Party Transactions (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Revenues | $ 2,321 | ||
Operating Expenses | $ 5,980,856 | 1,044,523 | |
President [Member] | |||
Equity Method Investment, Ownership Percentage | 51.00% | ||
Due from Related Parties | $ 425,328 | ||
Creative Edge [Member] | |||
Allowance for Doubtful Accounts Receivable, Write-offs | $ 167,456 | ||
R.X.N.B. [Member] | President [Member] | |||
Equity Method Investment, Ownership Percentage | 45.00% | ||
Revenues | $ 2,439,900 | ||
Construction in Progress, Gross | 1,542,000 | ||
Operating Expenses | $ 897,900 |
Note 14 - Contingencies and U51
Note 14 - Contingencies and Uncertainties (Details Textual) | Sep. 01, 2013CADa | Aug. 31, 2013USD ($) | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) |
Area of Land | a | 10.4 | |||
Operating Lease Annual Rent | CAD | CAD 339,000 | |||
Accrued Rent | $ 552,934 | $ 289,159 | ||
President [Member] | ||||
Employment Contract Term | 5 years | |||
Annual Salary | $ 1,200,000 |
Note 14 - Commitments and Conti
Note 14 - Commitments and Contingencies - Future Minimum Operating Lease Payments (Details) | Dec. 31, 2016CAD |
2,016 | CAD 339,000 |
2,017 | 339,000 |
2,018 | 84,750 |
Total | CAD 762,750 |
Note 16 - Business Segments (De
Note 16 - Business Segments (Details Textual) | 12 Months Ended |
Dec. 31, 2016 | |
Number of Operating Segments | 3 |
Note 17 - Subsequent Events (De
Note 17 - Subsequent Events (Details Textual) | 1 Months Ended | 3 Months Ended | 12 Months Ended | |
Jan. 30, 2017CAD | Mar. 31, 2017USD ($) | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | |
Proceeds from Convertible Debt | $ 1,167,412 | $ 270,074 | ||
Subsequent Event [Member] | ||||
Proceeds from Convertible Debt | $ 1,066,475 | |||
Subsequent Event [Member] | Common Stock [Member] | ||||
Debt Instrument, Convertible, Number of Equity Instruments | 666,547 | |||
Subsequent Event [Member] | Lease Arrangements Between The Lien Holder On The Property, The Landlord and CEN Biotech Regarding the Property at 20 North Rear Road [Member] | ||||
Operating Lease, Monthly Rent | CAD | CAD 4,000 |